Not FDA-approved2Evidence: Smaller human trialsSkin

Melanotan II1,2

Key takeaway

Melanotan II is a synthetic ring-shaped peptide of seven amino acids, recorded in FDA’s substance registry under the names Melanotan II and MT-II.1 Its human research is small and early: a 1996 pilot study in three men reported skin darkening and spontaneous erections, and a 2000 placebo-controlled study in 10 men with erectile dysfunction reported erections and nausea.6,7 FDA lists Melanotan II among compounding substances that may present significant safety risks, citing published case reports of serious adverse events including melanoma, a brain-swelling syndrome (PRES), a stimulant-like toxic reaction and priapism.2 No FDA approval is reported in the sources reviewed here, and Melanotan II is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.2,4

Melanotan II at a glance

What it isA synthetic cyclic peptide, N-acetyl-norleucyl-aspartyl-histidyl-D-phenylalanyl-arginyl-tryptophyl-lysinamide closed into a ring between its second and seventh units, according to FDA’s substance registry.1
FDA statusNo FDA approval is reported in the sources reviewed here. FDA lists Melanotan II among bulk substances whose compounding nominations were withdrawn and that may present significant safety risks.2
Human evidenceTwo very small early studies, published in 1996 and 2000, one of them placebo-controlled, plus published case reports of serious adverse events cited by FDA.2,6,7
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is Melanotan II?

Melanotan II is a synthetic peptide of seven units, N-acetyl-norleucine, aspartic acid, histidine, D-phenylalanine, arginine, tryptophan and lysinamide, with a bond closing the chain into a ring, according to FDA’s substance registry.1

The researchers who first tested it in people describe it as a ring-shaped analogue of alpha-melanocyte stimulating hormone (alpha-MSH) with very potent pigment-stimulating (melanotropic) activity in laboratory tests.6

How is Melanotan II thought to work?

As an analogue of alpha-MSH, it was studied for its effect on skin pigmentation, according to the 1996 pilot study.6

The authors of the 2000 study describe it as a synthetic melanotropic peptide that initiates erections. The FDA sources reviewed here do not describe its mechanism.2,7

What do human studies show?

In a 1996 pilot study, three healthy men received Melanotan II or saline on alternating days for two weeks. Two had increased pigmentation of the face, upper body and buttocks; mild nausea was common, one had marked sleepiness and fatigue, and spontaneous erections followed stretching and yawning.6

In a 2000 double-blind, placebo-controlled crossover study in 10 men with erectile dysfunction and organic risk factors, erections were reported after 12 of 19 Melanotan II treatments and 1 of 21 placebo treatments. Nausea and stretching or yawning were more common with Melanotan II, and 4 of 19 treatments caused severe nausea.7

FDA cites published case reports that discuss serious adverse events in people who used Melanotan II, including melanoma, posterior reversible encephalopathy syndrome (a form of brain swelling), sympathomimetic toxidrome (a stimulant-like poisoning) and priapism (a prolonged, painful erection).2

These studies were very small and short, and the FDA sources reviewed here do not evaluate whether Melanotan II is effective for any use.2,6,7

What the evidence base contains

  • Controlled human trial A double-blind, placebo-controlled crossover study in 10 men with erectile dysfunction and organic risk factors, published in 2000.7
  • Small, short, or incompletely reported human study A 1996 single-blind, placebo-controlled pilot study in three healthy men over two weeks.6
  • Small, short, or incompletely reported human study Published case reports, cited by FDA, of serious adverse events in people who used Melanotan II, including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism.2

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is Melanotan II FDA-approved?

None of the sources reviewed here reports an approval of Melanotan II by FDA.1,2

FDA’s compounding safety-risk page, current as of April 22, 2026, lists Melanotan II among bulk substances previously in category 2 whose nominations were withdrawn, citing possible immune reactions from aggregation or impurities and the case reports above.2

FDA’s page for the next meeting of its Pharmacy Compounding Advisory Committee, current as of April 15, 2026, lists Melanotan II among substances the committee will discuss for the 503A bulks list at a meeting before the end of February 2027, with the date not yet set.5

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Melanotan II is not among them.3,4

Timeline

  1. Results of a pilot study of Melanotan II in three men are published.6
  2. Results of a placebo-controlled crossover study of Melanotan II in 10 men with erectile dysfunction are published.7
  3. FDA’s advisory committee page lists Melanotan II for discussion at a meeting before the end of February 2027.5
  4. FDA’s compounding safety-risk page, as last updated, lists Melanotan II among withdrawn nominations with safety concerns.2

What is still unknown?

How often the serious adverse events in the case reports occur, since case reports cannot measure frequency or prove cause.2

Whether it is effective or safe for any condition: the two human studies reviewed here enrolled 13 men in total.6,7

What FDA’s advisory committee will conclude; its page did not give a meeting date.5

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Melanotan II: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Melanotan II are a bounded selection, not every registration or paper about Melanotan II. For the years before Melanotan II was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Melanotan II as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Melanotan II in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

No FDA approval reported; on FDA’s compounding safety-risk list. Two very small early human studies, one placebo-controlled in 10 men, report skin darkening, erections and nausea. FDA cites case reports of melanoma, brain swelling, stimulant-like toxicity and priapism. No FDA approval is reported, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Melanotan II?

No FDA approval reported; on FDA’s compounding safety-risk list. Two very small early human studies, one placebo-controlled in 10 men, report skin darkening, erections and nausea. FDA cites case reports of melanoma, brain swelling, stimulant-like toxicity and priapism. No FDA approval is reported, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
2
Source years
7
Drugs@FDA applications
0

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Collection changes

What did PeptideScanner add most recently?

  1. Literature metadata · added November 15, 2026

    CLIPSing Melanotan-II to Discover Multiple Functionally Selective hMCR Agonists.↗Source date March 7, 2026
  2. Literature metadata · added November 15, 2026

    5-Hydroxypyrroloindoline Affords Tryptathionine and 2,2'-bis-Indole Peptide Staples: Application to Melanotan-II.↗Source date April 8, 2024
  3. Literature metadata · added November 15, 2026

    Melanotan II User Experience: A Qualitative Study of Online Discussion Forums.↗Source date February 15, 2022

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected clinical trial records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Melanotan II?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

17Selected dated records
24Connected citations
7Populated source years2006–2026
2/4Record lanes present

Registered human studies

Trial composition

0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.

PubMed bibliography

Publication composition

16 of 16 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 14Research Support, Non-U.S. Gov't 3Case Reports 2Clinical Trial 2Comparative Study 2Controlled Clinical Trial 2Letter 2Research Support, U.S. Gov't, P.H.S. 2Clinical Trial, Phase I 1Research Support, N.I.H., Extramural 1Research Support, U.S. Gov't, Non-P.H.S. 1Review 1Validation Study 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
0
FDA Federal Register documents
1
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
17

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 17 dated records

Research hub

Explore the Melanotan II evidence record

Open all 17 records →
17Dated records
2Evidence types
17Cited public sources
7Source years

Change ledger

Recently changed for Melanotan II

Open all 18 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Profile updated

Melanotan II profile

We added two early human studies of Melanotan II and FDA’s advisory committee page listing it for a meeting before the end of February 2027.

PeptideScanner change date
November 16, 2026
Evidence lane
Profile
Record added

Federal Register notice 2016-27244

The Federal Register published notice 2016-27244, attributed to FDA and its parent HHS department, on 2016-11-14. Its official title is “Edward Manookian (Also Known as Ed Manning): Debarment Order,” and PeptideScanner's exact reviewed identity mapping connects the document to Melanotan II.

PeptideScanner change date
November 15, 2026
Cited source date
November 14, 2016
Evidence lane
Regulatory
Record added

Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II.

PubMed lists PMID 11035391 in International journal of impotence research as Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2000-10 (month precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
November 4, 2019
Evidence lane
Literature metadata

Official-source collections

Source records for Melanotan II

Open the full research atlas →
PubMed16

16 with attributed title, venue, publication-date, and type metadata.

  1. 5-Hydroxypyrroloindoline Affords Tryptathionine and 2,2'-bis-Indole Peptide Staples: Application to Melanotan-II.Chemistry (Weinheim an der Bergstrasse, Germany) · 2024 02 15
  2. CLIPSing Melanotan-II to Discover Multiple Functionally Selective hMCR Agonists.Journal of medicinal chemistry · 2022 02 21
  3. Melanotan II User Experience: A Qualitative Study of Online Discussion Forums.Dermatology (Basel, Switzerland) · 2021 08 31
Explore all selected literature →

Evidence types

Coverage by source year

Selected records span April 13, 2006 to March 7, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration1,2
  • U.S. Department of Health and Human Services3
Dated updates connected to this profile · 17

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    CLIPSing Melanotan-II to Discover Multiple Functionally Selective hMCR Agonists.↗

    PubMed lists PMID 35188390 in Journal of medicinal chemistry as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-02-21 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    5-Hydroxypyrroloindoline Affords Tryptathionine and 2,2'-bis-Indole Peptide Staples: Application to Melanotan-II.↗

    PubMed lists PMID 38285527 in Chemistry (Weinheim an der Bergstrasse, Germany) as Journal Article, with publication-date metadata of 2024-02-15 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Melanotan II User Experience: A Qualitative Study of Online Discussion Forums.↗

    PubMed lists PMID 34464955 in Dermatology (Basel, Switzerland) as Journal Article, with publication-date metadata of 2021-08-31 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    The first preparative solution phase synthesis of melanotan II.↗

    PubMed lists PMID 19043625 in Beilstein journal of organic chemistry as Journal Article, with publication-date metadata of 2008-10-30 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Melanotan II: a possible cause of renal infarction: review of the literature and case report.↗

    PubMed lists PMID 31953620 in CEN case reports as Case Reports, Journal Article, Review, with publication-date metadata of 2020-01-18 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    Combining MALDI mass spectrometry imaging and droplet-base surface sampling analysis for tissue distribution, metabolite profiling, and relative quantification of cyclic peptide melanotan II.↗

    PubMed lists PMID 32674774 in Analytica chimica acta as Journal Article, with publication-date metadata of 2020-05-24 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet.↗

    PubMed lists PMID 24771717 in Drug testing and analysis as Journal Article, Validation Study, with publication-date metadata of 2014-04-25 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II.↗

    PubMed lists PMID 11035391 in International journal of impotence research as Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2000-10 (month precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Literature metadata

    A comparison of HPLC and bioassay methods for plasma melanotan-II (MT-II) determination: application to a pharmacokinetic study in rats.↗

    PubMed lists PMID 7981427 in Biopharmaceutics & drug disposition as Comparative Study, Journal Article, Research Support, U.S. Gov't, P.H.S., with publication-date metadata of 1994-07 (month precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Literature metadata

    Evidence that Melanocortin Receptor Agonist Melanotan-II Synergistically Augments the Ability of Naltrexone to Blunt Binge-Like Ethanol Intake in Male C57BL/6J Mice.↗

    PubMed lists PMID 26108334 in Alcoholism, clinical and experimental research as Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S., with publication-date metadata of 2015-06-24 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Literature metadata

    Determination of melanotan II in rabbit urine using solid-phase extraction sample preparation followed by reversed-phase high-performance liquid chromatography.↗

    PubMed lists PMID 9106033 in Journal of chromatography. B, Biomedical sciences and applications as Journal Article, with publication-date metadata of 1997-03-07 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Literature metadata

    Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.↗

    PubMed lists PMID 8637402 in Life sciences as Clinical Trial, Clinical Trial, Phase I, Controlled Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S., with publication-date metadata of 1996 (year precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Melanotan II substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  2. 2
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  3. 3
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  4. 4
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  5. 5
    Meeting of the Pharmacy Compounding Advisory Committee (before the end of February 2027) · content current as of April 15, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  6. 6
    Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study (1996) · PMID 8637402 ↗

    Life Sciences · Official source · Source checked November 16, 2026

  7. 7
    Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction (2000) · PMID 11018622 ↗

    Urology · Official source · Source checked November 16, 2026